As global pharmaceutical companies intensify their focus on Asia-Pacific markets, Taiwan has emerged as a key strategic hub for pharmaceutical companies seeking to expand generic drug portfolios across the Asia-Pacific region , offering a stable regulatory environment, robust IP protection, and a high generic drug uptake under a universal healthcare system. Despite its relatively modest population, Taiwan punches above its weight in terms of healthcare spending and quality standards.
For manufacturers planning the Taiwan generic drug registration process, navigating the Taiwan Food and Drug Administration (TFDA) regulatory framework is critical. While Taiwan’s regulatory system is well-structured and aligned with international norms (ICH, PIC/S), its local nuances demand detailed planning and technical precision especially for generic drug submissions requiring bioequivalence and GMP alignment.
Taiwan generic drug registration is the regulatory process through which manufacturers obtain approval from the Taiwan Food and Drug Administration (TFDA) to market generic medicines in Taiwan. The process typically includes CTD dossier submission, bioequivalence evaluation, GMP compliance, and regulatory review.
Planning to Register Your Products in Taiwan?
DDReg Pharma provides end-to-end Regulatory Affairs Services, including regulatory strategy, product classification, CTD dossier preparation, TFDA submissions, local agent support, labeling compliance, and lifecycle management for pharmaceuticals, biologics, medical devices, and other life sciences products.
Explore Taiwan Regulatory Services →Taiwan's Regulatory Authority: TFDA
All processes related to the Taiwan generic drug registration process are overseen by the Taiwan Food and Drug Administration (TFDA), which operates under the Ministry of Health and Welfare (MOHFW).
What is TFDA? The TFDA is the national regulatory authority responsible for evaluating, approving, and monitoring generic drugs, new medicines, and pharmaceutical manufacturing compliance in Taiwan.
The TFDA operates a centralized drug review system and has made significant strides toward harmonizing its regulations with international standards, including those of the International Council for Harmonisation (ICH), the Pharmaceutical Inspection Co-operation Scheme (PIC/S), and relevant ASEAN regulatory initiatives.
The agency reviews Common Technical Document (CTD) dossiers, evaluates bioequivalence (BE) studies, verifies Good Manufacturing Practice (GMP) compliance, and grants marketing authorisation before pharmaceutical products can be marketed in Taiwan.
Why Should pharmaceutical companies register generic drugs in Taiwan?
- Pharmaceutical Market Size (2024): ~USD 7.6 billion
- Generics Penetration: Approximately 60% of all prescriptions
- Universal Health Coverage: National Health Insurance (NHI) promotes affordable generics
- Quality Expectations: High – Taiwan is a PIC/S member and aligns with ICH Q guidelines
Classification of Generic Drugs in Taiwan
In Taiwan, generic drugs are defined as:
“A product that is pharmaceutically equivalent or therapeutically equivalent to a reference listed drug (RLD), and has the same active ingredient(s), strength, dosage form, and route of administration.” — TFDA
Generic drugs are classified into two broad categories:
Classification | Requirement | Typical Evidence |
AB-rated Generic | Bioequivalence (BE) study required | In vivo BE study demonstrating equivalence to the Reference Listed Drug (RLD) |
Non-AB-rated Generic | BE waiver may be accepted | BCS-based biowaiver or in vitro equivalence with supporting scientific justification |
This classification determines whether manufacturers must conduct bioequivalence studies or can apply for a scientifically justified waiver during the registration process.
Key Regulatory Requirements for Taiwan Generic Drug Registration Process
Drug Master File (DMF) and CMC Documentation
- Full Chemistry, Manufacturing, and Controls (CMC) data
- Active Pharmaceutical Ingredient (API) sourced from GMP-compliant manufacturers
- Local site inspection may be triggered if GMP certification is not aligned with TFDA standards
Bioequivalence Studies (BE)
- BE studies are mandatory unless a waiver is justified (e.g., BCS Class I drugs)
- BE studies must be conducted at TFDA-approved CROs, or in countries whose BE data is accepted (e.g., US, EU, Japan under MRA)
Common Technical Document (CTD) Format
- Submissions must follow CTD structure (Modules 1–5)
- Taiwan uses a localized CTD format, closely aligned with ICH, but with specific TFDA preferences.
Pharmaceutical Inspection Cooperation Scheme (PIC/S) GMP Compliance
- Manufacturing sites (both local and foreign) must comply with PIC/S GMP standards
- On-site inspection or paper-based GMP certification review required .
Labelling and Packaging
- Labelling must be in Traditional Chinese
- Includes RLD comparison statements, indications, warnings, and dosage forms .
Stability Testing
- Must follow ICH Q1A (R2) guidelines
- Tropical zone stability data required (Zone IVb)
Regulatory Timelines for Taiwan Drug Approval Process
The Taiwan generic drug registration process typically takes approximately 9 to 12 months from dossier submission to final approval, although timelines may vary depending on the completeness of the application, bioequivalence (BE) data requirements, GMP inspections, and the complexity of the product under review.
Regulatory Stage | Typical Timeline |
Dossier Submission | Rolling (no fixed submission window) |
Administrative Screening | Approximately 30 working days |
Technical Review + BE Review | Approximately 180–270 working days |
Final Approval | Total approval timeline: approximately 9–12 months |
Note: Approval timelines are indicative and may vary depending on the completeness of the submission, regulatory queries, GMP inspection outcomes, and product-specific review requirements.
Best Practices for Taiwan Generic Drug Registration Process
- Early BE Planning – Many companies underestimate the BE expectations of the TFDA. Initiate BE studies early and ensure the protocol is aligned with TFDA preferences. Consider a pre-submission meeting with the TFDA for clarification.
- Choose a TFDA-Accepted CRO –TFDA maintains a list of accepted international BE centers. Using a recognized facility reduces the risk of repeat studies or rejection.
- Align with PIC/S GMP Early – Even if your facility holds US FDA or EU GMP certification, TFDA may require additional evidence or inspection. Early submission of a GMP Compliance Package is advisable.
- Local Representation is Mandatory – Foreign MA holders must appoint a Taiwan-registered agent for all interactions with TFDA. Choose one with proven regulatory expertise, especially for generics.
- Plan for NHI Reimbursement – Registration approval doesn’t guarantee NHI listing. Companies must apply separately to the National Health Insurance Administration (NHIA) and undergo price negotiation.
Recent Regulatory Developments (2023–2025)
- Digital Submissions: TFDA has begun piloting eCTD formats and digital platforms for drug applications.
- BE Guideline Updates: Revised in 2023 to strengthen requirements for highly variable drugs and modified-release formulations.
- Priority Review Pathways: In limited cases, TFDA offers accelerated review for essential generics or drugs under supply shortages.
Common Pitfalls to Avoid for Generic Drug Registration in Taiwan
- Incomplete or improperly localized CTD format
- Lack of acceptable BE data or improperly conducted BE studies
- Using API manufacturers without valid PIC/S GMP
- Submitting documents in English without certified Chinese translations
- Delays in GMP site inspections due to unclear documents or incomplete application
Recent Regulatory Developments For Drug Registration in Taiwan (2026)
- Expanded eCTD Implementation –The TFDA has broadened its scope of electronic Common Technical Document (eCTD) implementation. In 2026, TFDA expanded its eCTD implementation to additional categories of drug applications and thus encourages applicants to use electronic applications for new drug registrations and for the management of drug application Life Cycle activities.
- Continued Focus on Bioequivalence (BE) Requirements –TFDA continues to set high standards in the review of bioequivalence (BE) studies for the approval of generic drugs. TFDA expects sponsors to focus greater attention on the scientific conduct of BE studies, the quality of BE study data, and compliance with prevailing international standards. BE studies for complex and modified release dosage forms should be conducted in accordance with the updated TFDA guidelines at international BE study facilities.
- Greater Regulatory Harmonization – Taiwan is focusing greater attention on the International Conference on Harmonization (ICH) and the Pharmaceutical Inspection Co-operation Scheme (PIC/S) and is implementing risk-based approaches to enhance the evaluation of regulatory submissions and increase the efficiency of regulatory reviews.
- Enhanced Digital Regulatory Services – TFDA is applying digital technology to facilitate submission of dossiers and regulation, management, and review of the application Life Cycle. TFDA’s use of digital technology will facilitate more efficient processing of regulatory applications and greater transparency in the review process.
- Strengthened Post-Market Surveillance –TFDA continues to advance its expectations for post-market surveillance and pharmacovigilance. Marketing Authorization Holders (MAHs) are expected to establish and maintain effective risk management systems for the duration of the product Life Cycle. MAHs are also required to establish systems for the collection and reporting of adverse events and to monitor product quality.
This revised section incorporates insights on the TFDA’s anticipated regulatory direction through 2026, emphasizing eCTD application, sustained focus on bioequivalence, digitalization, international harmonization, and post-market supervision.
Conclusion
Taiwan represents a strategically important generic market in Asia. While regulatory expectations are rigorous, they are also transparent and increasingly aligned with global norms. Success hinges on proactive regulatory planning, robust BE study execution, PIC/S GMP compliance, and clear localization strategies.
By partnering with experienced local regulatory experts and planning submissions with precision, companies can reduce approval timelines, avoid rejections, and maximize market access in Taiwan’s competitive generics space.
How can DDReg help?
DDReg offers end-to-end regulatory strategy, dossier preparation, BE study planning, and local representation services for Taiwan and other APAC markets. Need Help Navigating Taiwan’s Generic Drug Registration Pathway? Contact our team of experts to ensure smooth and compliant entry into Taiwan.
Read more from DDReg experts here: Navigating SAHPRA: A Guide for Complementary and Traditional Health Products in South Africa
Frequently Asked Questions (FAQs)
The Taiwan Generic Drug Registration Process is the regulatory pathway established by the Taiwan Food and Drug Administration (TFDA) for approving generic medicines before they can be marketed in Taiwan. Applicants must submit a Common Technical Document (CTD), demonstrate bioequivalence (BE) where required, comply with PIC/S Good Manufacturing Practice (GMP) standards, and meet all applicable quality, safety, and efficacy requirements.
A BCS Biowaiver is a provision that allows certain immediate release oral dosage forms that satisfy certain requirements of the Biopharmaceutics Classification System (BCS) and certain dissolution criteria to be granted a Biowaiver for the in vivo bioequivalence studies
A typical application includes a CTD dossier (Modules 1–5), Chemistry, Manufacturing, and Controls (CMC) documentation, Drug Master File (DMF) information where applicable, bioequivalence study data or an approved waiver, GMP compliance documentation, stability data, and labelling in Traditional Chinese.